Dilon nets three-year gamma imaging deal with GPO
Dilon Technologies, a manufacturer of a gamma imaging system for early breast cancer detection, has signed a three-year agreement with Amerinet, a national group purchasing organization (GPO).
The contract offers Amerinet’s 26,000 acute and non-acute healthcare providers and their patients’ access to the Dilon 6800 Gamma Camera for detecting and diagnosing early stage breast cancers, according to the Newport News-based Dilon.
The company said its Dilon 6800 performs a molecular breast imaging technique called Breast-Specific Gamma Imaging (BSGI), which can detect lesions independent of tissue density and discover early stage cancers. BSGI serves as a complementary diagnostic adjunct procedure to mammography and ultrasound.
The contract offers Amerinet’s 26,000 acute and non-acute healthcare providers and their patients’ access to the Dilon 6800 Gamma Camera for detecting and diagnosing early stage breast cancers, according to the Newport News-based Dilon.
The company said its Dilon 6800 performs a molecular breast imaging technique called Breast-Specific Gamma Imaging (BSGI), which can detect lesions independent of tissue density and discover early stage cancers. BSGI serves as a complementary diagnostic adjunct procedure to mammography and ultrasound.